| PROGRAM |

​DAY 2

21 November 2018

TOXICOLOGY

 
07:30 – 08:00     
Registration / Coffee
 
08:05 – 08:35
Safety assessment from new therapeutic concept to candidate selection
Mr James Smith
Boehringer-Ingelheim Pharmaceuticals Inc. | USA
 
08:35 – 09:10
General toxicology program to support first in human trials for  small molecules
Dr Danuta Herzyk
Merck Sharp & Dohme | USA
 
09:10 – 09:40
Toxicology beyond first in human trials
Dr Danuta Herzyk
Boehringer-Ingelheim Pharmaceuticals Inc. | USA
 
10:00 – 10:15
Tea / Coffee
 
11:00 – 11:45
Pathologist perspective on adverse vs Non-adverse 
Dr Ken Frazier
GlaxoSmithKline | USA
 
12:15 – 13:00
Biologics development and immunotoxicology
Dr Danuta Herzyk
Merck Sharp & Dohme | USA
 
14:15 – 14:45
Emerging Technologies in therapeutic platforms
Dr Danuta Herzyk
Merck Sharp & Dohme | USA
 
15:15 – 15:30
Discussion
 
15:45 – 16:30
Designing new GA mouse line for preclinical research
Dr Sarah Wells
MRC Harwell  (IMPC) | UK
 
18:30 – 22:00
Boehringer-Ingelheim AG Traditional South African Braai function
 
08:00 – 08:05  
Nonclinical Safety Session Introduction
Mr James Smith
Boehringer-Ingelheim Pharmaceuticals Inc. | USA
 
10:15 – 11:00
Pathologist perspective on target organ toxicity
Dr Ken Frazier
GlaxoSmithKline | USA
 
09:40 – 10:00
Discussion
 
11:45 – 12:15
Discussion
 
13:00 – 14:15
European research infrastructure for mouse disease models 
Lunch  /  Talk by Dr Asrar Ali Khan
INFRAFRONTIER GmbH | Germany
 
14:45 – 15:15
Carcinogenicity case study
Dr James Smith
Boehringer-Ingelheim Pharmaceuticals Inc. | USA
 
15:30 – 15:45
Tea / Coffee
 
16:30 – 17:00
Phenotyping mice for drug development
Dr Tertius Hough
MRC Harwell  (IMPC) | UK